ArticlePharmacoepidemiology and drug safety2014
Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.
Article in Pharmacoepidemiology and drug safety, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Executive summary of the guideline for prescribing opioid analgesics for chronic non-cancer pain (third edition) by the Japan Society of Pain Clinicians.Journal of anesthesia · 2025Guideline
- Abuse-deterrent formulations and opioid-related harms in North Carolina, 2010-2018.American journal of epidemiology · 2025Article
- Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study.Substance abuse treatment, prevention, and policy · 2024Article
- State-Level Prevalence and Associates of Opioid Dependence in the USA.International journal of environmental research and public health · 2022Article
- Optimising Medicines Administration for Patients with Dysphagia in Hospital: Medical or Nursing Responsibility?Geriatrics (Basel, Switzerland) · 2020Article
- Repeated blast model of mild traumatic brain injury alters oxycodone self-administration and drug seeking.The European journal of neuroscience · 2019Article
- Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting.Addiction (Abingdon, England) · 2019Article
- Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids.American economic journal. Economic policy · 2018Article
- Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2018Article
- Patterns of Opioid Prescribing for an Orthopaedic Trauma Population.Journal of orthopaedic trauma · 2017Article
- Prescription opioid poisoning across urban and rural areas: identifying vulnerable groups and geographic areas.Addiction (Abingdon, England) · 2017Article
- The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.Clinical pharmacology and therapeutics · 2016Article
- Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.Clinical pharmacokinetics · 2016Review
- Drug Formulation Advances in Extended-Release Medications for Pain Control.Current pain and headache reports · 2016Review
- Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program.Journal of managed care & specialty pharmacy · 2016Article
- Article
- Tamper-resistant drugs cannot solve the opioid crisis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2015Article
- Estimating the health care burden of prescription opioid abuse in five European countries.ClinicoEconomics and outcomes research : CEOR · 2015Article
- The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability.Journal of pain research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAbuse of opioid analgesics for their psychoactive effects is associated with a large number of fatalities. The effect of making opioid tablets harder to crush/dissolve on opioid-related fatalities has not been assessed. The objective of this study was to assess the impact of introducing extended-release oxycodone (ERO [OxyContin(®) ]) tablets containing physicochemical barriers to crushing/dissolving (reformulated ERO) on deaths reported to the manufacturer.
methodsAll spontaneous adverse event reports of death in the US reported to the manufacturer between 3Q2009 and 3Q2013 involving ERO were used. The mean numbers of deaths/quarter in the 3 years after reformulated ERO introduction were compared with the year before. Changes in the slope of trends in deaths were assessed using spline regression. Comparison groups consisted of non-fatal reports involving ERO and fatality reports involving ER morphine.
resultsReports of death decreased 82% (95% CI: -89, -73) from the year before to the third year after (131 to 23 deaths per year) reformulation; overdose death reports decreased 87% (95% CI: -93, -78) and overdose deaths with mention of abuse-related behavior decreased 86% (95% CI:-92, -75). In contrast, non-fatal ERO reports did not decrease post-reformulation, and reported ER morphine fatalities remained unchanged. The ratio of ERO fatalities to all oxycodone fatalities decreased from 21% to 8% in the year pre-reformulation to the second year post-reformulation.
conclusionsThese findings, when considered in the context of previously published studies using other surveillance systems, suggest that the abuse-deterrent characteristics of reformulated ERO have decreased the fatalities associated with its misuse/abuse. © 2014 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.